Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.
about
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive reviewCheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting.Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy.An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trialsChemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients.Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens.Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapyA randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.Low Enrollment of Adolescents and Young Adults Onto Cancer Trials: Insights From the Community Clinical Oncology ProgramControl of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimensA Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients.Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy.Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.Antiemetic prescribing practices using a computerized physician order entry system.Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials.State of the Art Antiemetic Therapy for Cancer Patients.2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.Nausea and disturbed sleep as predictors of cancer-related fatigue in breast cancer patients: a multicenter NCORP study.Novel management of postoperative pain using only oral analgesics after LADG.Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting.Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients' experience.
P2860
Q28081186-6D18A8BD-2B39-428D-8490-0218E474D1C7Q33866119-0F6ED6EA-9E45-4515-B4DA-69D2BF80DDF1Q34563594-A2B863A8-00E4-45F6-8316-07B1C5E29CC1Q34588516-412845EC-5094-4E29-9547-3A78AE2F0B5EQ35789229-83F73894-3269-41CE-8CA5-F88388CAAB93Q36064834-CC31BF0C-E9BA-41AE-80CA-FD19ED37B359Q36640676-761964AF-AD7C-4B96-ABC1-F94A0C4FE22CQ36764931-60446E9A-63C9-46FE-AE0E-041062CF6982Q36778149-E0B53733-9006-4DE3-876F-96E54179EAAFQ37111164-6DD4B178-EFE4-4053-982F-BDB47835AB99Q37125017-0DC7ECD7-1B97-48BD-8937-D1B926EA237AQ37139336-A76421BD-E130-45CC-A084-139F9577CB47Q37245902-5DEE6AB4-5BF7-4F7A-A7CC-A59773CABB58Q37480802-3DCE7AA5-A9FA-4831-9179-B8C20058D8C4Q37609798-69749E7B-2127-484E-B37B-4BA9FC5D5872Q37697769-3DEF201F-5B37-4E1D-B28F-B1B8D4F61663Q37736060-3931E8FC-9956-4D82-9A78-73E437C4FEB8Q38132238-F15E2FA9-FED4-4CD7-B32D-47AB5C98CD50Q38192940-830F7982-06A1-46B3-BBDC-12C567EAC6C7Q38676452-F3527773-B721-4BBA-BD64-A9E35B974172Q38904462-BD6AF9D6-8007-4508-94D0-5476A008DA0FQ39084993-9944E4A4-FD1A-4D98-84AE-98E7E60F6CE1Q39192104-6832CF18-5FD1-4D97-88DD-1979D609586EQ40143472-D9300CFC-0A04-4F1C-87B0-4C0E68EDE7F3Q41644259-AE7ABAA3-A2DA-46EF-9F88-BFA720C09E98
P2860
Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Prevention of delayed nausea: ...... tients receiving chemotherapy.
@ast
Prevention of delayed nausea: ...... tients receiving chemotherapy.
@en
type
label
Prevention of delayed nausea: ...... tients receiving chemotherapy.
@ast
Prevention of delayed nausea: ...... tients receiving chemotherapy.
@en
prefLabel
Prevention of delayed nausea: ...... tients receiving chemotherapy.
@ast
Prevention of delayed nausea: ...... tients receiving chemotherapy.
@en
P2093
P2860
P356
P1476
Prevention of delayed nausea: ...... tients receiving chemotherapy.
@en
P2093
Charles E Heckler
Gary R Morrow
J Philip Kuebler
James L Wade
Joseph A Roscoe
Shaker R Dakhil
Supriya G Mohile
P2860
P304
P356
10.1200/JCO.2011.39.8123
P407
P577
2012-08-20T00:00:00Z